Laramo

Lacosamide, the active ingredient in Laramo, is a sodium channel blocker presented as a tablet/oral for oral use. It is used to treat partial‑onset seizures in patients with epilepsy. GNH USA supplies Laramo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures (epilepsy): reduces seizure frequency as adjunctive therapy in focal epilepsy. - Adjunctive therapy for refractory focal epilepsy: provides additional seizure control when other antiepileptics are insufficient. - Epilepsy in adults and children (≥4 years): approved for use as part of a comprehensive seizure management plan.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness or imbalance. - Nausea: mild to moderate gastrointestinal upset. - Headache: occasional tension‑type headache. - Fatigue: feeling unusually tired or weak. - Blurred vision: temporary visual disturbances. - Diplopia: double vision, especially at higher doses.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmias. - Suicidal ideation: emergence of depressive thoughts or behaviors. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Respiratory depression: especially when combined with other CNS depressants.

When prescribing or dispensing lacosamide, consider the following safety measures. - Renal impairment: assess kidney function and adjust dosing if necessary. - Hepatic impairment: monitor liver enzymes and use caution in patients with liver disease. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation or arrhythmias. - Pregnancy: safety not established; weigh potential benefits against risks. - Concomitant CNS depressants: monitor for additive sedation or respiratory effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic concentrations. - Class III antiarrhythmics (e.g., amiodarone): additive effects on cardiac conduction.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate, phenobarbital): may require dose adjustments. - Alcohol: potentiates central nervous system depression. - Tricyclic antidepressants: increased risk of dizziness and cardiac effects.